Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart ...

By Michael Erman NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims ...

What To Know: The weakness appears linked to Novo Nordisk’s decision to slash the U.S. self-pay price of its popular GLP-1 drugs, Wegovy and Ozempic, from $499 to $349 per month, intensifying pressure ...

Digital healthcare platforms are expanding across both consumer wellness and precision medicine, with Hims & Hers Health, Inc. HIMS and Tempus AI, Inc. TEM operating in distinct segments of the market ...

Many investors have fallen in love with Hims & Hers (HIMS) because weight-loss drugs have been a powerful catalyst for this emerging tele-health company’s initial growth. HIMS kept at weight loss ...

Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. HIMS's recurring revenue model, 70%+ gross margins, and rapid subscriber ...

Shares of Hims & Hers Health, Inc. (NASDAQ: HIMS) are trending Thursday morning. The San Francisco-based telehealth company announced an international expansion. What To Know: Hims & Hers announced ...